IC
ZYNE

Ikarian Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Ikarian Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-692,500
Closed -$2.33M – 221
2020
Q2 		$2.33M Buy
+692,500
New +$3.27M 0.19% 99

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ikarian Capital's ZYNE Position: Q3 2020 in Review

Ikarian Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 647,400 shares — an estimated $2.18M sold.

Ikarian Capital first reported a position in ZYNE in Q2 2020 and held it in 1 quarter. The position peaked at $2.18M in Q2 2020. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

  • Ikarian Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Ikarian Capital sold 647,400 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $2.18M.
  • Ikarian Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2020 and held it in 1 quarter.
  • Ikarian Capital's Zynerba Pharmaceuticals, Inc position peaked at $2.18M in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.